Objective:
To evaluate the efficacy and safety of 8 mg aflibercept in patients with neovascular age-related macular degeneration (AMD) during the PULSAR extension trial.
Key Findings:
- Patients switching from 2 mg to 8 mg maintained vision and extended treatment intervals.
- 80% of patients in the 8 mg group could extend treatment intervals to 12 weeks or longer.
- No new safety signals, including glaucoma or retinal occlusive events, were observed over 3 years.
- A reduction in central subfield thickness and fluid was noted after switching to 8 mg.
Interpretation:
The PULSAR extension trial supports the use of 8 mg aflibercept as a safe and effective treatment option for neovascular AMD, with potential benefits in treatment frequency and visual outcomes.
Limitations:
- The study was open-label, which may introduce bias.
- Long-term effects beyond 3 years are not yet known.
Conclusion:
The findings suggest that high-dose aflibercept can provide sustained visual acuity and structural benefits in AMD patients, supporting its use in clinical practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
